ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Regulation FD Disclosure

ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

On January3, 2018, Accuray Incorporated (“Accuray”) issued a press release announcing its irrevocable election to the indenture dated as of April24, 2014 (the “SeriesA Indenture”) with respect to its 3.50% SeriesA Convertible Senior Notes due February1, 2018 (the “SeriesA Notes”) to pay cash up to $1,000 for each $1,000 principal amount of SeriesA Notes converted and deliver shares of its common stock for the conversion value, if any, in excess of $1,000 (other than cash in lieu of any fractional share) (the “Net Share Settlement Election”). Holders of the SeriesA Notes may convert their notes at any time prior to close of business on the business day immediately preceding February1, 2018. Accuray will pay holders who do not convert their SeriesA Notes principal plus accrued and unpaid interest in cash on February1, 2018.

The press release related to the Net Share Settlement Election is furnished as Exhibit99.1 to this Current Report on Form8-K. In accordance with General Instruction B.2 of Form8-K, the information in Exhibit99.1 and in this Item shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.


EX-99.1 2 a18-2151_1ex99d1.htm EX-99.1 Exhibit 99.1   Accuray Elects Net Share Settlement for 3.50% Series A Convertible Senior Notes Due 2018 Company will pay principal in cash and deliver shares for any excess conversion value   SUNNYVALE,…
To view the full exhibit click here


Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

An ad to help with our costs